Gastroenterologycirculating tumour DNAcolorectal cancer
Harnessing Circulating Tumour DNA for Minimal Residual Disease Detection in Colorectal Cancer: Insights from the INTERCEPT Programme
By MedXY|Oct 3, 2026
The INTERCEPT study demonstrates that longitudinal ctDNA testing effectively detects minimal residual disease post-curative treatment in colorectal cancer, enhancing recurrence prediction and refining risk stratification to guide future int